Last updated on November 2017

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part B)


Brief description of study

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part B)

Detailed Study Description

You are being asked to take part in this research study because you were diagnosed with a type of cancer called melanoma. Although your melanoma has been removed by surgery, you are at risk for having the melanoma come back (recur). People who are at risk for melanoma recurrence are usually followed closely by their doctor to watch for the development of melanoma, and may receive drug treatments such as interferon alpha-2b, which is approved by the U.S. Food and Drug Administration (FDA) and other international regulatory authorities. For patients who are followed and treated the usual way for melanoma recurrence, less than 60 out of 100 are free of cancer five years after their melanoma was removed by surgery.

Clinical Study Identifier: TX8163

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Pamela Treas

Baptist Health Clinical Research Center & Lexington Cardiac Research Foundation
Lexington, KY USA
  Connect »